Okazaki M, Yamamura J, Kawasaki Y, Ohtsuru M, Kobayakawa K, Yasuda S, Oka H, Yamamura M, Hayashi Y
Dept. of Surgery, Kobe Ekisaikai Hospital.
Gan To Kagaku Ryoho. 2001 Dec;28(13):2073-7.
We report a case of advanced gastric cancer producing Alpha Fetoprotein (AFP) with multiple liver metastases in which TS-1 is effective. Prognosis of gastric cancer producing AFP is well known to poor. A 74-year-old female was admitted complaining of anemia. She was diagnosed as having advanced gastric cancer with multiple liver metastases producing AFP by endoscopy, computed tomography and angiography. Her serum AFP level was 17,666 ng/ml and her serum CEA level was 5-2 ng/ml. After transarterial embolization (TAE), her family rejected her operation because it would not be curative. So, she was treated with TS-1, 40 mg, administered orally every day, followed by 14 days rest, as the first course. The next was TS-1, 80 mg orally administered for 6 courses. Her serum AFP level was down from 17,666 ng/ml to 94 ng/ml after 6 courses of TS-1. CT revealed that liver metastases did not change and endoscopy showed the primary lesion has diminished. Our report is the first to demonstrate that TS-1 is effective for patients with advanced gastric cancer producing AFP with multiple liver metastases.
我们报告一例产生甲胎蛋白(AFP)的晚期胃癌伴多发肝转移,其中TS-1治疗有效。众所周知,产生AFP的胃癌预后较差。一名74岁女性因贫血入院。通过内镜检查、计算机断层扫描和血管造影,她被诊断为患有产生AFP的晚期胃癌伴多发肝转移。她的血清AFP水平为17,666 ng/ml,血清癌胚抗原(CEA)水平为5.2 ng/ml。经动脉栓塞术(TAE)后,其家人因手术无法治愈而拒绝手术。于是,她接受TS-1治疗,每日口服40 mg,随后休息14天作为第一个疗程。接下来是TS-1,口服80 mg,共6个疗程。经过6个疗程的TS-1治疗后,她的血清AFP水平从17,666 ng/ml降至94 ng/ml。CT显示肝转移灶未改变,内镜检查显示原发灶缩小。我们的报告首次证明TS-1对产生AFP的晚期胃癌伴多发肝转移患者有效。